---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: MT-4129-E01"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: MT-4129-E01. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 57 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence/mt-4129-e01"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: MT-4129-E01

<a id="heading-3.1.7"></a>

## 3.1.7 MT-4129-E01

<a id="heading-3.1.7.1"></a>

### 3.1.7.1 Objective

<a id="topic-3.1.7.1-1"></a>

#### Safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses

> “This study aimed to characterize the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of lorundrostat in healthy adult participants.”
> “This first‐in‐human dose escalation study evaluates the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple oral doses of lorundrostat, a highly selective CYP11B2 inhibitor. In addition, this study also compared lorundrostat PK in females and males and older adult (≥65 years old) and younger adult participants.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.1-2"></a>

#### Registered purpose and official title

> “The purpose of this study is to investigate the safety and tolerability of ascending single and multiple oral doses of MT-4129 in healthy subjects.”
> “A Randomised, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of MT-4129 in Healthy Subjects; Including the Effect of Gender and Age on the Pharmacokinetics of a Single Dose of MT-4129 in Healthy Subjects”

Source: [ClinicalTrials.gov NCT02953132](https://clinicaltrials.gov/study/NCT02953132)

<a id="topic-3.1.7.1-3"></a>

#### Concentration-QTc evaluation within the first-in-human study

> “The effect of lorundrostat on the QTc interval was assessed as part of a first-in-human study with 64 participants who received a single dose of lorundrostat 5-800 mg or placebo (single ascending dose [SAD]) and 36 participants who received multiple doses of lorundrostat 40-360 mg/day or placebo for 7 days (multiple ascending dose [MAD])”

Source: [Tortorici et al. (2024)](https://mineralystx.com/wp-content/uploads/2024/09/83964-ACCP-Poster-2024-09-03v2.pdf)

<a id="heading-3.1.7.2"></a>

### 3.1.7.2 Location and Study Date

<a id="topic-3.1.7.2-1"></a>

#### Single center in the Netherlands, November 2016 to May 2017

> “A four‐part, randomized, double‐blind, placebo‐controlled, first‐in‐human study was performed (single‐center in the Netherlands; November 16, 2016–May 01, 2017)”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.2-2"></a>

#### Registered site, sponsor, and dates

| Field | Quoted record |
| --- | --- |
| Location | “Pharmaceutical Research Associates (PRA) Health Sciences” |
| Sponsor | “Tanabe Pharma Corporation” |
| Other study ID number | “MT-4129-E01” |
| Study start | “2016-11” |
| Primary completion (actual) | “2017-05” |
| Study completion (actual) | “2017-05” |

Source: [ClinicalTrials.gov NCT02953132](https://clinicaltrials.gov/study/NCT02953132)

<a id="topic-3.1.7.2-3"></a>

#### Ethics approval and contract research organization

> “The study was approved by the local independent ethics committee; the BEBO foundation in Assen, Netherlands; and the Central Committee on Research Involving Human Subjects in The Hague, Netherlands; and conducted according to the provisions of the Declaration of Helsinki.”
> “Thijs van Iersel and Jan Jaap van Lier are employees of ICON, the CRO which conducted the clinical study.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="heading-3.1.7.3"></a>

### 3.1.7.3 Study Design

<a id="topic-3.1.7.3-1"></a>

#### Four-part, randomized, double-blind, placebo-controlled design

> “A four‐part, randomized, double‐blind, placebo‐controlled, first‐in‐human study was performed (single‐center in the Netherlands; November 16, 2016–May 01, 2017) to determine the safety, tolerability, PK, and PD of single ascending doses (SADs; part 1) and multiple ascending doses (MADs; part 2) of lorundrostat free base in a capsule in healthy participants (EudraCT Number: 2016–003500‐32).”
> “The study also assessed sex‐ (part 3) and age‐related (part 4) effects on the PK of a single dose of lorundrostat.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.3-2"></a>

#### Exploratory food comparison

> “An exploratory comparison of the effect of food on PK profiles of lorundrostat was also performed by assessing single‐dose PK profiles of lorundrostat in the fasted state (part 1) vs. PK profiles of lorundrostat in the fed state (part 2 after the first‐dose administered).”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.3-3"></a>

#### Sentinel dosing and dose escalation rules

> “All cohorts included two sentinel participants of whom one received lorundrostat and one received matching placebo. The remaining six participants, of whom five received lorundrostat and one received placebo, were dosed ≥24 h later.”
> “Doses were administered in an ascending order per cohort. After each cohort, all safety data were reviewed prior to initiating the next dose cohort.”
> “Progression to the next dose level was based on available data from part 1 and the preceding dose cohort in part 2.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.3-4"></a>

#### Registered design details

| Field | Quoted record |
| --- | --- |
| Phase | “Phase 1” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Double” |
| Primary purpose | “Other” |

Source: [ClinicalTrials.gov NCT02953132](https://clinicaltrials.gov/study/NCT02953132)

<a id="topic-3.1.7.3-5"></a>

#### Holter electrocardiograms matched to pharmacokinetic sampling

> “Serial ECGs were extracted from continuous recordings (Holter) at prespecified time points and were matched with blood collections for pharmacokinetic analysis through 24 hours postdose on Day 1 in the SAD study and on Days 1 and 7 in the MAD study”

Source: [Tortorici et al. (2024)](https://mineralystx.com/wp-content/uploads/2024/09/83964-ACCP-Poster-2024-09-03v2.pdf)

<a id="heading-3.1.7.4"></a>

### 3.1.7.4 Eligibility Criteria

<a id="topic-3.1.7.4-1"></a>

#### Healthy Caucasian men, women, and older men

> “Healthy male Caucasian participants (parts 1 and 2) aged 18–55 years (inclusive), healthy non‐pregnant and non‐lactating female Caucasian participants (part 3) aged 18–55 years (inclusive), and healthy male Caucasian participants aged ≥65 years (part 4) were eligible.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.4-2"></a>

#### Registered inclusion and exclusion criteria

> “Healthy and free from clinically significant illness or disease”
> “Male or female subjects aged 18 to 55 years or elderly male subjects aged ≥65”
> “A body weight of ≥60 kg for males and ≥50 kg for females, and a body mass index ranging from 18 to 30 kg/m2”
> “Clinically significant endocrine, thyroid, hepatic, respiratory, gastro intestinal, neurological, renal, cardiovascular disease, or history of any significant psychiatric/psychotic illness disorder”

Source: [ClinicalTrials.gov NCT02953132](https://clinicaltrials.gov/study/NCT02953132)

<a id="heading-3.1.7.5"></a>

### 3.1.7.5 Treatment

<a id="topic-3.1.7.5-1"></a>

#### Part 1: single ascending doses of 5 to 800 mg, fasted

> “In part 1, in each dose cohort, six participants were randomized to receive a single dose of lorundrostat and two participants were randomized to receive matching placebo in the fasted state.”
> “The dosing cohorts were 5, 10, 20, 50, 100, 200, 400, and 800 mg (5‐mg starting dose rationale provided in Table S1).”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.5-2"></a>

#### Part 2: once-daily doses of 40, 120, or 360 mg for 7 days, fed

> “In part 2, in each cohort, nine participants received daily doses of lorundrostat and three participants received matching placebo in the fed state from Day 1 to Day 7.”
> “The final dose levels of lorundrostat for part 2 were 40, 120, and 360 mg. An adrenocorticotropic hormone (ACTH) challenge test was performed on Day ‐2 and Day 6 to evaluate the lorundrostat selectivity for aldosterone synthesis.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.5-3"></a>

#### Parts 3 and 4: single 100 mg dose in women and in men aged 65 years or older

> “In one cohort of eight females (part 3) and one cohort of eight males aged ≥65 years (part 4), six participants were randomized to receive a single 100‐mg dose of lorundrostat and two participants were randomized to receive matching placebo in the fasted state in each part. The results were compared with those at the same dose in part 1.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.5-4"></a>

#### Capsule formulation relative to the phase 2 tablet

> “The lorundrostat capsule formulation used in the first‐in‐human studies reported here is equivalent to ~50% of exposure seen in the tablet formulation used in the phase II study (doses used in the phase II study included 12.5 mg once daily and twice daily, 25 mg twice daily, 50 mg once daily, and 100 mg once daily).”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="heading-3.1.7.6"></a>

### 3.1.7.6 Study Outcomes

<a id="heading-3.1.7.6.1"></a>

#### 3.1.7.6.1 Rationale for Using Adverse Events as the Primary Endpoint

<a id="topic-3.1.7.6.1-1"></a>

##### Registered primary outcome measures

| Primary outcome measure | Time frame |
| --- | --- |
| “Safety and Tolerability as measured by incidence and severity of adverse events” | “Up to Day 14” |
| “Safety and Tolerability as measured by vital signs” | “Up to Day 14” |
| “Safety and Tolerability as measured by ECG” | “Up to Day 14” |
| “Safety and Tolerability as measured by clinical laboratory assessments” | “Up to Day 14” |
| “Safety and Tolerability as measured by Hormone assessments” | “Up to Day 10” |
| “Safety and Tolerability as measured by physical examination” | “Up to Day 14” |

Source: [ClinicalTrials.gov NCT02953132](https://clinicaltrials.gov/study/NCT02953132)

<a id="topic-3.1.7.6.1-2"></a>

##### Safety assessments in the publication

> “Safety assessments included treatment‐emergent adverse events (TEAEs), treatment‐related TEAEs, vital signs, 12‐lead electrocardiograms (ECGs), clinical laboratory evaluations, and physical examinations.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.6.1-3"></a>

##### Purpose of phase 1 studies in federal regulation

> “Phase 1 includes the initial introduction of an investigational new drug into humans. Phase 1 studies are typically closely monitored and may be conducted in patients or normal volunteer subjects. These studies are designed to determine the metabolism and pharmacologic actions of the drug in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.”
> “During Phase 1, sufficient information about the drug's pharmacokinetics and pharmacological effects should be obtained to permit the design of well-controlled, scientifically valid, Phase 2 studies.”

Source: [Electronic Code of Federal Regulations, 21 CFR 312.21 (2026)](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-B/section-312.21)

<a id="topic-3.1.7.6.1-4"></a>

##### Rationale for cortisol and ACTH-stimulation safety assessments

> “CYP11B1, a key enzyme in glucocorticoid biosynthesis, has a high homology to CYP11B2 (>93%). High selectivity for CYP11B2 over CYP11B1 is an essential characteristic for a successful aldosterone synthase inhibitor.”
> “Osilodrostat, the first aldosterone synthase inhibitor, lacked high selectivity, resulted in blunted adrenocorticotropic hormone‐stimulated cortisol release in some patients, and instead became a treatment for Cushing's disease.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.6.1-5"></a>

##### Rationale for the concentration-QTc analysis

> “Regulatory guidance recommends that the effects of new drug candidates on ventricular depolarization and subsequent repolarization (QT interval) be rigorously investigated”
> “regulatory guidance documents allow for a waiver of a thorough QT study in the case that a >10 ms effect on the heart-rate corrected QT (QTc) interval at clinically relevant drug concentrations can be excluded”
> “The primary analysis was an assessment of the relationship of the plasma concentration of lorundrostat and change from baseline in QTc, corrected for HR using Fridericia’s method (ΔQTcF)”
> “The secondary analysis was a by-timepoint analysis of ΔQTcF for lorundrostat versus placebo”

Source: [Tortorici et al. (2024)](https://mineralystx.com/wp-content/uploads/2024/09/83964-ACCP-Poster-2024-09-03v2.pdf)

<a id="topic-3.1.7.6.1-6"></a>

##### Registered secondary pharmacokinetic and pharmacodynamic outcome measures

> “Maximum observed plasma concentration (Cmax) of MT-4129”
> “Apparent terminal elimination half-life (t1/2) of MT-4129”
> “Renal clearance (CLR) of MT-4129”
> “Plasma aldosterone”
> “Serum cortisol”
> “Urinary sodium”

Source: [ClinicalTrials.gov NCT02953132](https://clinicaltrials.gov/study/NCT02953132)

<a id="heading-3.1.7.7"></a>

### 3.1.7.7 Statistical Analysis Description

<a id="heading-3.1.7.7.1"></a>

#### 3.1.7.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.7.7.1-1"></a>

##### Participants screened and randomized

> “A total of 245 participants were screened, of which 116 were randomized.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

| Field | Quoted record |
| --- | --- |
| Enrollment (estimated) | “116” |

Source: [ClinicalTrials.gov NCT02953132](https://clinicaltrials.gov/study/NCT02953132)

<a id="topic-3.1.7.7.1-2"></a>

##### Participants per part

> “Part 1 (SAD) included 64 male participants between 18 and 55 years old. Part 2 (MAD) included 36 male participants between 19 and 54 years of age. Part 3 (sex effect) included eight female participants between 20 and 35 years of age. Part 4 (age effect) included eight male participants between 68 and 80 years of age.”
> “The overall incidence of TEAEs was comparable between participants treated with lorundrostat (41/87 [47%]) and those treated with placebo (18/29 [62%]).”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.7.1-3"></a>

##### Participants in the concentration-QTc analysis groups

> “The SAD and MAD QT/QTcF analysis groups included 60 (46 lorundrostat, 14 placebo) and 32 (23 lorundrostat, 9 placebo) healthy participants, respectively”

Source: [Tortorici et al. (2024)](https://mineralystx.com/wp-content/uploads/2024/09/83964-ACCP-Poster-2024-09-03v2.pdf)

<a id="heading-3.1.7.7.2"></a>

#### 3.1.7.7.2 Description of Analysis Sets

<a id="topic-3.1.7.7.2-1"></a>

##### Safety, pharmacokinetic, and pharmacodynamic analysis sets

> “Safety analyses used the safety analysis set (all participants who received at least one dose of study drug).”
> “All PK analyses used the PK analysis set (all participants who received at least one dose of study drug other than placebo and had PK data considered sufficient and interpretable).”
> “All PD analyses used the PD analysis set (all participants who received at least one dose of study drug, had at least one post‐dose PD assessment, and PD data considered sufficient and interpretable).”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.7.2-2"></a>

##### Dose proportionality, sex, age, and food comparisons

> “Dose proportionality was concluded if the 95% confidence interval (CI) for slope (β) included the value 1.”
> “Difference in least square means and corresponding 90% CI were back‐transformed to obtain the estimates of geometric mean ratios and their CI for females vs. males and participants ≥ 65 years old vs. 18–55 years old. The result was judged to be statistically significant if the 90% CI did not include 1.”
> “No formal statistical comparison was performed for an exploratory comparison of PK between fasted (part 1) and fed (part 2, after the first‐dose administered) states.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.7.2-3"></a>

##### Pharmacokinetic and QTc analysis set

> “The relationship of lorundrostat plasma concentration and the ΔΔQTcF was assessed in the PK/QTc analysis set (defined as all participants with ≥1 set of PK and ΔQTcF data from the same time point) using linear mixed-effects modeling with ΔQTcF as the dependent variable, lorundrostat concentration as the explanatory variable, and treatment and time as fixed effects.”
> “All cardiodynamic analyses were performed separately for the SAD and MAD studies”

Source: [Tortorici et al. (2024)](https://mineralystx.com/wp-content/uploads/2024/09/83964-ACCP-Poster-2024-09-03v2.pdf)

<a id="heading-3.1.7.8"></a>

### 3.1.7.8 Results

<a id="heading-3.1.7.8.1"></a>

#### 3.1.7.8.1 Participant Disposition

<a id="topic-3.1.7.8.1-1"></a>

##### Completion by part

> “All participants randomized in parts 1, 3, and 4 completed the study as per protocol. One participant in part 2 did not complete the study.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.8.1-2"></a>

##### Withdrawal for sinus tachycardia in the 360 mg cohort

> “One participant in cohort 3 of part 2 was withdrawn on Day 2 because of an AE of sinus tachycardia (117 bpm) before dosing on Day 2, and he received only one dose of 360 mg lorundrostat on Day 1 (Table 2).”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="heading-3.1.7.8.2"></a>

#### 3.1.7.8.2 Baseline Characteristics

<a id="topic-3.1.7.8.2-1"></a>

##### Race and ethnicity of participants

> “All participants were white and none were of Hispanic or Latino ethnicity.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.8.2-2"></a>

##### Demographics by dose group and part

| Dose group | Age, years, mean (SD) | Sex, n (%) | Weight, kg, mean (SD) | BMI (kg/m2), mean (SD) |
| --- | --- | --- | --- | --- |
| Part 1, placebo (n = 16) | “31.2 (12.9)” | Male: “16 (100)” | “81.0 (7.8)” | “24.8 (2.1)” |
| Part 1, 5 mg (n = 6) | “29.0 (12.3)” | Male: “6 (100)” | “71.5 (5.3)” | “22.5 (1.8)” |
| Part 1, 10 mg (n = 6) | “31.7 (13.1)” | Male: “6 (100)” | “78.3 (12.4)” | “23.9 (3.7)” |
| Part 1, 20 mg (n = 6) | “27.5 (12.7)” | Male: “6 (100)” | “76.2 (7.6)” | “23.8 (2.8)” |
| Part 1, 50 mg (n = 6) | “28.2 (13.8)” | Male: “6 (100)” | “77.3 (7.2)” | “22.8 (2.2)” |
| Part 1, 100 mg (n = 6) | “27.8 (11.9)” | Male: “6 (100)” | “79.2 (8.7)” | “23.4 (1.9)” |
| Part 1, 200 mg (n = 6) | “28.3 (11.8)” | Male: “6 (100)” | “81.4 (12.3)” | “23.4 (2.3)” |
| Part 1, 400 mg (n = 6) | “28.5 (11.9)” | Male: “6 (100)” | “84.2 (6.8)” | “24.2 (2.8)” |
| Part 1, 800 mg (n = 6) | “33.2 (15.8)” | Male: “6 (100)” | “85.1 (9.9)” | “25.1 (2.9)” |
| Part 2, placebo (n = 9) | “29.3 (11.9)” | Male: “9 (100)” | “78.5 (10.2)” | “23.6 (2.9)” |
| Part 2, 40 mg (n = 9) | “29.2 (10.4)” | Male: “9 (100)” | “76.7 (8.6)” | “23.0 (2.3)” |
| Part 2, 120 mg (n = 9) | “26.3 (5.6)” | Male: “9 (100)” | “77.8 (12.2)” | “22.8 (2.6)” |
| Part 2, 360 mg (n = 9) | “30.8 (11.6)” | Male: “9 (100)” | “76.4 (11.7)” | “23.1 (4.1)” |
| Part 3, placebo (n = 2) | “23.0 (4.2)” | Female: “2 (100)” | “59.9 (8.9)” | “22.3 (3.3)” |
| Part 3, 100 mg (n = 6) | “25.5 (5.8)” | Female: “6 (100)” | “60.8 (4.7)” | “22.2 (1.7)” |
| Part 4, placebo (n = 2) | “72.5 (3.5)” | Male: “2 (100)” | “77.2 (10.6)” | “27.9 (1.0)” |
| Part 4, 100 mg (n = 6) | “72.2 (4.1)” | Male: “6 (100)” | “77.9 (6.3)” | “25.1 (1.9)” |

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.8.2-3"></a>

##### Baseline electrocardiogram parameters

> “For both groups, mean baseline ECG parameters were consistent with those from healthy populations, with mean QTcF between 388.7 and 401.0 ms (SAD) and 394.8 and 402.1 ms (MAD)”

Source: [Tortorici et al. (2024)](https://mineralystx.com/wp-content/uploads/2024/09/83964-ACCP-Poster-2024-09-03v2.pdf)

<a id="heading-3.1.7.8.3"></a>

#### 3.1.7.8.3 Efficacy Results

<a id="topic-3.1.7.8.3-1"></a>

##### In vitro selectivity for CYP11B2 over CYP11B1

> “Lorundrostat inhibited hCYP11B2 and hCYP11B1 with inhibition constant values of 1.27 nmol/L and 475 nmol/L, respectively. These results indicate that lorundrostat inhibits CYP11B2 with 374‐fold selectivity over CYP11B1 (Figure 1).”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.8.3-2"></a>

##### Single-dose pharmacokinetics

> “Following single oral doses across 5–800 mg, plasma drug concentration–time profiles demonstrated rapid absorption with a median time to maximum concentration (T max) 1.0–1.5 h (Table 3; Figure 1b); the mean terminal half‐life (t 1/2) ranged from 7.9 to 10.5 h, and apparent clearance was comparable, ranging from 18.7 to 27.6 L/h.”
> “In contrast, the estimate of the slope (95% CI) for C max versus dose was 1.104 (1.043–1.164), and a slightly greater than dose proportional increase in C max was observed over the range 5–800 mg (Figure S1).”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.8.3-3"></a>

##### Multiple-dose pharmacokinetics and accumulation

> “A steady state was achieved by approximately Day 5 and very slight accumulation of lorundrostat was observed following multiple dosing compared with Day 1, with the mean rate of accumulation values for AUC0–24 ranging from 1.15 to 1.19 across the entire dose range. Consistent with single‐dose administration, the mean t 1/2 values on Day 7 ranged from 9.1 to 11.9 h.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.8.3-4"></a>

##### Plasma pharmacokinetic parameters by dose

| Dose group | AUC, ng × h/mL, mean (SD) | Cmax, ng/mL, mean (SD) | t1/2, h, mean (SD) | Tmax, h, median (minimum–maximum) |
| --- | --- | --- | --- | --- |
| Single dose, 5 mg (AUC0–∞) | “232 (25)” | “36.7 (6.7)” | “8.3 (0.7)” | “1.5 (1.0–3.0)” |
| Single dose, 10 mg (AUC0–∞) | “452 (46)” | “76.3 (20.4)” | “7.9 (0.9)” | “1.3 (1.0–1.5)” |
| Single dose, 20 mg (AUC0–∞) | “770 (183)” | “140.6 (76.1)” | “10.0 (1.9)” | “1.5 (1.0–3.0)” |
| Single dose, 50 mg (AUC0–∞) | “2157 (259)” | “572.8 (205.7)” | “9.1 (1.9)” | “1.0 (0.5–3.0)” |
| Single dose, 100 mg (AUC0–∞) | “5376 (495)” | “1211.0 (248.3)” | “10.0 (0.9)” | “1.5 (0.5–3.0)” |
| Single dose, 200 mg (AUC0–∞) | “10,660 (3483)” | “2847.5 (1015.2)” | “9.9 (3.6)” | “1.3 (1.0–3.0)” |
| Single dose, 400 mg (AUC0–∞) | “17,275 (2906)” | “4454.8 (862.4)” | “9.7 (2.3)” | “1.3 (0.5–3.0)” |
| Single dose, 800 mg (AUC0–∞) | “29,385 (3623)” | “7708.5 (1617.1)” | “10.5 (2.1)” | “1.5 (0.5–4.0)” |
| Multiple dose, 40 mg, Day 7 (AUC0–24) | “1795.0 (312.0)” | “365.1 (46.5)” | “9.1 (1.8)” | “2.0 (1.0–3.0)” |
| Multiple dose, 120 mg, Day 7 (AUC0–24) | “5816.0 (1315.0)” | “1038.7 (342.8)” | “11.9 (2.5)” | “1.5 (0.5–5.0)” |
| Multiple dose, 360 mg, Day 7 (AUC0–24) | “21825.0 (3955.0)” | “3812.1 (1282.3)” | “9.2 (2.5)” | “2.5 (1.0–4.0)” |

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.8.3-5"></a>

##### Urinary excretion of unchanged drug and renal clearance

> “After a single dose of 40–360 mg of lorundrostat on Day 1, the fraction of the dose excreted in the urine as unchanged was low, with mean values ranging between 1.2%–1.8%.”
> “After 7 days of once‐daily doses of lorundrostat, the fraction of the dose excreted in the urine as unchanged drug was low for all multiple‐dose levels, with mean values ranging between 2.3% and 2.6%. The fraction of the lorundrostat dose excreted remained consistent over the multiple‐dose range tested. Renal clearance was low and generally similar across all multiple‐dose levels (mean CLR ranging between 0.4 and 0.6 L/h on Day 7).”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.8.3-6"></a>

##### Effects of sex, age, and food on pharmacokinetics

> “In part 3 of the study, after a single 100‐mg dose of lorundrostat, there was no statistically significant difference between lorundrostat exposure in females and males (Table S4).”
> “In part 4, there was no statistically significant difference between older adult and younger adult lorundrostat exposures (Table S4).”
> “Based on the dose escalation data of the first cohort in part 2 where lorundrostat was administered in the fed state, the PK profile did not appear to be affected compared with part 1 where lorundrostat was administered in the fasted state.”
> “Separate from the study we report in this article, a formal food effect study has been conducted and confirms lack of effect of food on the absorption and PK of lorundrostat (tablet formulation; data on file).”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.8.3-7"></a>

##### Plasma aldosterone suppression after single doses

> “At the lower dose levels (lorundrostat 5–50 mg), the PAC returned to values near baseline within 24 h post‐dose. At the higher dose levels (lorundrostat 100–800 mg), the reduction of PAC was sustained until 24 h post‐dose. PAC showed maximum decreases at 4 h and 8 h post‐dose of ~80% compared with placebo. Single doses of lorundrostat, ranging from 10 to 800 mg reduced the AUC0–24 for PAC in a dose‐dependent manner, with statistically significant decreases ranging from 36% to 77% vs. placebo (Figure 2b; Table S5) without effecting cortisol (Figure 2c).”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.8.3-8"></a>

##### Aldosterone after multiple doses and rebound after the last dose

> “Consistent with the SAD cohorts, multiple‐dose lorundrostat data demonstrated that for all dose levels tested, PAC decreased in an apparent dose‐dependent manner between 2 and 12 h post‐dose on Day 7 (Figure 2d). From 24 h after the last dose on Day 7, a clear rebound in PAC ranging from 73% to 163% compared with placebo was observed at all multiple‐dose levels of lorundrostat. These increases were sustained at least until Day 10, 3 days after the last dose.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.8.3-9"></a>

##### ACTH-stimulated aldosterone and cortisol

> “During non‐ACTH challenge conditions, no relevant changes from baseline were observed for serum cortisol concentrations and plasma 11‐deoxycortisol concentrations during multiple dosing of lorundrostat. At all multiple‐dose levels, lorundrostat completely blunted the ACTH‐stimulated aldosterone response on Day 6 compared with placebo, while there was no effect on the cortisol response.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.8.3-10"></a>

##### Renin activity, 11-deoxycorticosterone, and urinary sodium

> “Once‐daily administration of lorundrostat at doses ranging from 40 to 360 mg increased plasma renin activity and serum 11‐DOC compared with placebo (Figure 3a,b).”
> “Urine sodium and urinary log10 (10 × Na+/K+) ratio were increased at all dose levels tested in the SAD, consistent with reduced aldosterone signaling (Figure 3d). In the MAD, the urine sodium and urinary log10 (10 × Na+/K+) ratio was initially increased on Day 1 at all dose levels, but the ratio returned to baseline levels at the next sampling timepoint at the end of the dosing period on Day 7.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.8.3-11"></a>

##### Implications for dose selection

> “Given that the PD effects on renal electrolyte regulation were near maximum at 120 mg daily and the excessive 11‐DOC accumulation observed at dose of 360 mg once daily, the data suggest that the dose selection for the treatment of hypertension should avoid the higher dose level and focus on doses up to 120 mg daily.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="heading-3.1.7.8.4"></a>

#### 3.1.7.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.7.8.5"></a>

#### 3.1.7.8.5 Safety Results

<a id="topic-3.1.7.8.5-1"></a>

##### Serious and overall treatment-emergent adverse events

> “Lorundrostat was well tolerated and no serious TEAEs occurred during the study.”
> “The overall incidence of TEAEs was comparable between participants treated with lorundrostat (41/87 [47%]) and those treated with placebo (18/29 [62%]). Across all cohorts, dizziness (of mild intensity) was reported by nine (10.3%) lorundrostat‐treated participants compared with one (3.4%) placebo‐treated participant.”
> “There were no clinically significant findings with respect to clinical laboratory, vital signs, ECGs, or physical examination.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.8.5-2"></a>

##### Treatment-related adverse events after single doses

| Preferred term, n (%) | Placebo (n = 16) | 5 mg (n = 6) | 10 mg (n = 6) | 20 mg (n = 6) | 50 mg (n = 6) | 100 mg (n = 6) | 200 mg (n = 6) | 400 mg (n = 6) | 800 mg (n = 6) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Headache | “2 (12.5)” | “0 (0.0)” | “0 (0.0)” | “1 (16.7)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “1 (16.7)” | “0 (0.0)” |
| Somnolence | “1 (6.3)” | “0 (0.0)” | “0 (0.0)” | “1 (16.7)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” |
| Dizziness | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “1 (16.7)” | “0 (0.0)” |
| Diarrhea | “0 (0.0)” | “0 (0.0)” | “1 (16.7)” | “0 (0.0)” | “0 (0.0)” | “1 (16.7)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” |
| Nausea | “1 (6.3)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” |
| Asthenia | “1 (6.3)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” |

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.8.5-3"></a>

##### Treatment-related adverse events after multiple doses

| Preferred term, n (%) | Part 2, placebo (n = 9) | Part 2, 40 mg (n = 9) | Part 2, 120 mg (n = 9) | Part 2, 360 mg (n = 9) |
| --- | --- | --- | --- | --- |
| Headache | “2 (22.2)” | “1 (11.1)” | “1 (11.1)” | “0 (0.0)” |
| Dizziness postural | “0 (0.0)” | “1 (11.1)” | “1 (11.1)” | “1 (11.1)” |
| Somnolence | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “1 (11.1)” |
| Dizziness | “0 (0.0)” | “0 (0.0)” | “1 (11.1)” | “0 (0.0)” |
| Dysgeusia | “0 (0.0)” | “1 (11.1)” | “0 (0.0)” | “0 (0.0)” |
| Sinus tachycardia | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “1 (11.1)” |
| Dyspnea | “1 (11.1)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” |
| Nausea | “0 (0.0)” | “1 (11.1)” | “0 (0.0)” | “0 (0.0)” |

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

> “There were no treatment‐related TEAEs in the Sex Effect Part 3 cohort.”
> “These observations suggest that a stimulus–response reaction to some of the study procedures was more plausible than a relationship to the study drug.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.8.5-4"></a>

##### Serum potassium during multiple dosing

> “Within 2 days of initiation of lorundrostat treatment, serum potassium rose in all three dose cohorts (part 2) by group mean values ranging from 0.28 to 0.38 mmol/L and remained elevated throughout the remainder of the 7 days of treatment. There was a maximum mean increase of 0.44 mmol/L after 40 mg on Day 8, 0.6 mmol/L after 120 mg on Day 7, and 0.48 mmol/L after 360 mg on Day 6. None of the subjects reached the stopping criterion for potassium of 6.0 mmol/L.”
> “Upon cessation of lorundrostat treatment, serum potassium levels rapidly fell toward pretreatment baseline.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.8.5-5"></a>

##### Concentration-QTc results

> “On the basis of this analysis, an effect on placebo-corrected ΔQTcF (ΔΔQTcF) >10 ms can be excluded within the observed range of plasma lorundrostat concentrations up to ~7800 ng/mL”
> “On the basis of the MAD results, an effect on ΔΔQTcF exceeding 10 ms can be excluded within the observed range of plasma lorundrostat concentrations up to ~6175 ng/mL”
> “There were no participants in the SAD and MAD studies with QTcF >450 ms or ΔQTcF >30 ms”

Source: [Tortorici et al. (2024)](https://mineralystx.com/wp-content/uploads/2024/09/83964-ACCP-Poster-2024-09-03v2.pdf)

<a id="topic-3.1.7.8.5-6"></a>

##### Exposure margin and waiver of a thorough QT study

> “These results demonstrate the absence of QT interval prolongation by plasma exposure of up to approximately 7800 ng/mL lorundrostat”
> “This concentration is 4.8-fold higher than the predicted maximum observed plasma concentration (Cmax) at the maximum clinically efficacious dosage of 100 mg once daily and is also higher than the high clinical exposure scenario when lorundrostat is given with strong CYP3A4 inhibitors (~1.2-fold increase in Cmax)”
> “On the basis of these data, the regulatory requirement for a thorough QT study was waived”

Source: [Tortorici et al. (2024)](https://mineralystx.com/wp-content/uploads/2024/09/83964-ACCP-Poster-2024-09-03v2.pdf)

<a id="topic-3.1.7.8.5-7"></a>

##### Heart rate, PR, and QRS intervals

> “In both the SAD and MAD studies and at all studied doses, lorundrostat did not have clinically relevant effects on the other assessed cardiodynamic and ECG parameters”
> “In the categorical analyses, there was 1 bradycardic outlier at 1 time point in the SAD study”
> “There were no outliers for HR in the MAD study, or for PR or QRS (both studies)”

Source: [Tortorici et al. (2024)](https://mineralystx.com/wp-content/uploads/2024/09/83964-ACCP-Poster-2024-09-03v2.pdf)

<a id="heading-3.1.7.9"></a>

### 3.1.7.9 Study Limitations

<a id="topic-3.1.7.9-1"></a>

#### Summary

MT-4129-E01 randomized 116 healthy white participants at one center in the Netherlands. Parts 1 and 2 enrolled men aged 18 to 55 years only, and the effects of sex and of age were each assessed in one cohort of 8 participants, 6 of whom received a single 100 mg dose. Multiple dosing lasted 7 days, so the study gives no information on longer treatment or on people with hypertension. Lorundrostat was given as a capsule whose exposure the authors state is about 50% of that of the tablet used in the phase 2 study, the comparison of fed and fasted pharmacokinetics was exploratory with no formal statistical comparison, and the formal tablet food effect study is described as “data on file”. The ClinicalTrials.gov record lists enrollment as estimated. The concentration-QTc analysis is reported in a congress poster by authors from Mineralys Therapeutics and Clario. The publication states that the studies it reports were funded by Mineralys Therapeutics, while the registry record names Tanabe Pharma Corporation as sponsor, and the authors include employees of Mitsubishi Tanabe Pharma Corporation, Mineralys Therapeutics, and ICON, the contract research organization that conducted the study.

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/); [ClinicalTrials.gov NCT02953132](https://clinicaltrials.gov/study/NCT02953132); [Tortorici et al. (2024)](https://mineralystx.com/wp-content/uploads/2024/09/83964-ACCP-Poster-2024-09-03v2.pdf)

<a id="topic-3.1.7.9-2"></a>

#### Healthy male participants in the dose-escalation parts

> “Oral administration of lorundrostat, either as single dose up to 800 mg under fasted conditions (SAD part 1) or as once‐daily dose up to 360 mg for 7 days under fed conditions (MAD part 2), was well tolerated with a favorable safety profile in a group of healthy male participants.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.9-3"></a>

#### Duration of sodium depletion not addressed

> “Although the urinary electrolyte measurements confirmed that there was a brief period of natriuresis at all doses tested, the duration and stability of the sodium depletion is not addressed by that measurement.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.9-4"></a>

#### Funding and author affiliations

> “All studies reported in this manuscript were funded by Mineralys Therapeutics, Inc.”
> “Hidetoshi Shimizu, Yoshiyasu Ohta, Kei Ogawa, Sheikh Mohammed Ashfaq Rahman, Aya Fujii, Yuki Hiraga, Mizue Kawai, and Kanami Sugimoto‐Kawabata are employees of Mitsubishi Tanabe Pharma Corporation, which invented and out‐licensed the compound to Mineralys Therapeutics, Inc.”
> “Michael A. Tortorici, Stephen Djedjos, and David M. Rodman are employees of Mineralys Therapeutics, Inc.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.9-5"></a>

#### Sponsorship of the concentration-QTc analysis

> “The study was sponsored by Mineralys Therapeutics (Radnor, PA, USA).”
> “MAT and DAR: Employment: Mineralys Therapeutics; BD: Employment: Clario; stock ownership: Clario; HX: Employment: Clario; SS: Consultant: Mineralys Therapeutics.”

Source: [Tortorici et al. (2024)](https://mineralystx.com/wp-content/uploads/2024/09/83964-ACCP-Poster-2024-09-03v2.pdf)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
